Davis, California – Croda Pharma and BSI announced that they have entered into a strategic collaboration agreement to support the sustainable sourcing of pharmaceutical grade adjuvant QS-21, a potent component of adjuvant systems. QS-21 is used in several innovative vaccines against diseases such as shingles, malaria and RSV, plus promising new vaccine and immunotherapy treatments such as cancer. This partnership sees the two organisations share expertise to bring to market QS-21 from Quillaja saponaria plant cell culture, delivering the most sustainable source of the adjuvant from plantlets in contrast with conventional methods that harvest mature trees to extract material from
The post Croda and Botanical Solution Inc. (BSI) partner to fast-track sustainable vaccine adjuvant QS-21 production appeared first on Pharma Mirror Magazine.
